Navigation Links
S*BIO to Initiate Global Phase 3 Clinical Trials of its Novel JAK2 Inhibitor Pacritinib for Treatment of Myelofibrosis (MF)
Date:10/25/2011

SINGAPORE, Oct. 25, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced plans to initiate a global Phase 3 clinical program of its novel JAK2 inhibitor pacritinib (SB1518), in the first half of 2012 to further demonstrate its activity and tolerability for the treatment of myelofibrosis (MF). The company is actively exploring partnering opportunities for the advancement of its leading JAK2 program.

"Data from Phase 1 and 2 clinical studies have demonstrated that pacritinib is well tolerated and active in the treatment of myelofibrosis, an orphan disease with a high unmet medical need," said Tamar Howson, interim CEO and board member of S*BIO. "We are moving forward with an aggressive and focused development plan with global Phase 3 trials for pacritinib to further demonstrate its clinical benefits in MF patients and to maximise the value of our JAK2 program. We are currently in the process of identifying a suitable partner for the Phase 3 studies and pacritinib's subsequent commercialization."

The primary objective of the double-blind, placebo-controlled Phase 3 studies is to compare the efficacy of pacritinib versus placebo in achieving clinically significant reduction in spleen size in MF patients with splenomegaly. Secondary outcomes of both studies include patient-reported change in the most bothersome symptom identified at baseline, duration of response, as well as overall survival. The trials will enrol up to 500 MF patients.

In Phase 2 studies, treatment with pacritinib resulted in sustained reduction in MF-associated splenomegaly with no evidence of myelosuppression and no exacerbation of cytopenias. Pacritinib is a small molecule JAK2-selective kinase inhibitor that demonstrated high potency in preclinical models against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequency in myeloproliferative disorders such as MF. More than 50% of patients with MF possess the JAK2
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. S*BIO Restructures Agreement With Onyx for JAK2 Inhibitor Program
3. S*BIOs Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models
4. S*BIOs JAK2 Inhibitor SB1518 Granted Orphan Drug Designation by European Commission (EC) for the Treatment of Myelofibrosis (MF)
5. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
6. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
7. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
8. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
9. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
10. CareFusion Initiates Class I Recall of EnVe Ventilators
11. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...   Polymer Technology Systems, Inc. (PTS) ... to integrate the CardioChek ® PA ... health systems across the country. The CardioChek PA ... through Hanson Medical Systems , offers immediate, ... cholesterol, triglycerides, and glucose. (Logo: ...
(Date:6/17/2013)... Quebec , June 17, 2013 Valeant Pharmaceuticals ... announced today that it has filed a preliminary prospectus supplement ... has today made a similar filing with securities regulatory authorities ... in connection with a public offering of its common ... "Offering"). The Company will also grant to the ...
(Date:6/17/2013)... , June 17, 2013  A little known drug industry ... scrutiny by the U.S. Supreme Court – and a ruling ... could not have come at a better time for New ... from the Rx industry tactic are all too apparent in ... 50+ New Yorkers, state residents are in a near Rx ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 2Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 3
... (NYSE Amex: ANX ) today announced the closing ... of its common stock and warrants exercisable for up to ...  The securities sold in the offering were sold in a ... 0.5 of a share at a price to the public ...
... 16, 2011 An analysis of the TRITON-TIMI 38 ... American Heart Association (AHA) Scientific Sessions meeting examined the ... death, myocardial infarction [MI] and stroke) compared to clopidogrel ... in acute coronary syndrome (ACS) patients with ST-segment elevation ...
Cached Medicine Technology:ADVENTRX Announces Closing of Public Offering 2ADVENTRX Announces Closing of Public Offering 3New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 2New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 3New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 4New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 5New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 6New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 7New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 8
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... Lesbian, Gay, Bisexual and Transgender (LGBT) Pride ... sexual minority youth are still at greater ... according to the Suicide Prevention Resource Center. ... recently published recommendation to improve psychologists, treatment ... improve psychological functioning and reduce depression and ...
(Date:6/18/2013)... system using a person,s DNA was announced as ... London Startup Competition, Europe,s largest technology conference. ... on University of Bristol research by its founders, ... Professor of Bioinformatics in the University,s Department of ... to be one of 16 finalists in the ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 ... Stevie® Award in the Company of the Year category ... last night. , The American Business Awards are the ... the U.S.A. are eligible to submit nominations – public ... , Nicknamed the Stevies for the Greek word for ...
(Date:6/18/2013)... cough outbreaks are more likely to die prematurely even ... in Sweden has found. Women had a 20% higher ... 40%. Women also suffered more complications during and after ... as infant death within the first month of life. ... patients with exposure to whooping cough in childhood, particularly ...
Breaking Medicine News(10 mins):Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Sexual minority youth need specialized treatment from therapists 2Health News:CyraCom International, Inc. Honored as a Gold Stevie® Award Winner in 2013 American Business Awards 2Health News:CyraCom International, Inc. Honored as a Gold Stevie® Award Winner in 2013 American Business Awards 3
... MADISON, N.J., Nov. 8 Wyeth (NYSE: WYE ... Suisse First Boston,Healthcare Conference on Tuesday, November 13, 2007 ... Joseph M. Mahady, Senior Vice President,Wyeth and President, Wyeth ... live for investors at, http://www.wyeth.com and available for ...
... Mutual and Ohio Farm Bureau,Federation (OFBF) have announced ... to OFBF,s more than 230,000 members. Effective ... access to,Medical Mutual,s SuperMed provider network, the most ... providers in Ohio. Medical,Mutual and OFBF have worked ...
... for injury, study finds , THURSDAY, Nov. 8 (HealthDay ... medications may cut their risk for fracture, Canadian researchers ... there,s an increased risk of additional fractures, other health ... in osteoporosis patients are hip, spine, and wrist fractures. ...
... Focusing on his experience as a physician in ... Harris, MD, FACP, president-elect of the American College of ... Committee Subcommittee on Regulations, Healthcare and Trade. , ... financial struggles that Medicare payments to physicians played on ...
... Va. (Nov. 8, 2007) Virginia Commonwealth University researchers ... that play a major role in clotting disorders, which ... the lungs and those localized deep in the body ... occur when the effect of thrombin, a protein involved ...
... Nov. 8 Pathwork Diagnostics, a,genomics-based diagnostics company ... Origin Test is the focus of two studies ... Meeting of the Association,for Molecular Pathology (November 7-10, ... help determine a tumor,s origin so that,tissue-specific management ...
Cached Medicine News:Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 2Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 3Health News:Sticking With Meds Lowers Elderly Fracture Risk 2Health News:Looming Medicare cuts will disproportionately hurt physicians in small practices 2Health News:Researchers identify molecules with interesting anti-clotting properties 2Health News:Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics' Tissue of Origin Test 2Health News:Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics' Tissue of Origin Test 3
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
Clear Vinyl Urethral Catheters (100% Latex Free)...
100% Silicone Foley Catheter Kits 2-Way...
Medicine Products: